Detection and Characterization of Lung Cancer Using Cell-free DNA Fragmentomes

Non-invasive approaches for cell-free DNA (cfDNA) assessment provide an opportunity for cancer detection and intervention. Here, we use a machine learning model for detecting tumor-derived cfDNA through genome-wide analyses of cfDNA fragmentation in a prospective study of 365 individuals at risk for lung cancer. We validate the cancer detection model using an independent cohort of 385 non-cancer individuals and 46 lung cancer patients. Combining fragmentation features, clinical risk factors, and CEA levels, followed by CT imaging, detected 94% of patients with cancer across stages and subtypes, including 91% of stage I/II and 96% of stage III/IV, at 80% specificity. Genome-wide fragmentation profiles across ~13,000 ASCL1 transcription factor binding sites distinguished individuals with small cell lung cancer from those with non-small cell lung cancer with high accuracy (AUC = 0.98). A higher fragmentation score represented an independent prognostic indicator of survival. This approach provides a facile avenue for non-invasive detection of lung cancer.

Citing Articles

Multimodal Framework in Lung Cancer Management: Integrating Liquid Biopsy with Traditional Diagnostic Techniques.

Qi W, Tian L, Xu J, Li Z, Wang T Cancer Manag Res. 2025; 17:461-481.

PMID: 40060704 PMC: 11889406. DOI: 10.2147/CMAR.S506630.

Transparency and Representation in Clinical Research Utilizing Artificial Intelligence in Oncology: A Scoping Review.

DAmiano A, Cheunkarndee T, Azoba C, Chen K, Mak R, Perni S Cancer Med. 2025; 14(5):e70728.

PMID: 40059400 PMC: 11891267. DOI: 10.1002/cam4.70728.

A deep-learning model for quantifying circulating tumour DNA from the density distribution of DNA-fragment lengths.

Zhu G, Rahman C, Getty V, Odinokov D, Baruah P, Carrie H Nat Biomed Eng. 2025; .

PMID: 40055581 DOI: 10.1038/s41551-025-01370-3.

Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection.

Bruhm D, Vulpescu N, Foda Z, Phallen J, Scharpf R, Velculescu V Nat Rev Cancer. 2025; .

PMID: 40038442 DOI: 10.1038/s41568-025-00795-x.

Circulating cell-free DNA methylation profiles as noninvasive multiple sclerosis biomarkers: A proof-of-concept study.

Fu H, Huang K, Zhu W, Zhang L, Bandaru R, Wang L medRxiv. 2025; .

PMID: 40034794 PMC: 11875267. DOI: 10.1101/2025.02.14.25322180.

References

DAddario G, Fruh M, Reck M, Baumann P, Klepetko W, Felip E . Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 Suppl 5:v116-9. DOI: 10.1093/annonc/mdq189. View

Jiang L, Huang J, Higgs B, Hu Z, Xiao Z, Yao X . Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer. PLoS Genet. 2016; 12(4):e1005895. PMC: 4836692. DOI: 10.1371/journal.pgen.1005895. View

Borromeo M, Savage T, Kollipara R, He M, Augustyn A, Osborne J . ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs. Cell Rep. 2016; 16(5):1259-1272. PMC: 4972690. DOI: 10.1016/j.celrep.2016.06.081. View

Adalsteinsson V, Ha G, Freeman S, Choudhury A, Stover D, Parsons H . Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017; 8(1):1324. PMC: 5673918. DOI: 10.1038/s41467-017-00965-y. View

Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm D . Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. 2019; 570(7761):385-389. PMC: 6774252. DOI: 10.1038/s41586-019-1272-6. View

Hokari S, Tamura Y, Kaneda A, Katsura A, Morikawa M, Murai F . Comparative analysis of TTF-1 binding DNA regions in small-cell lung cancer and non-small-cell lung cancer. Mol Oncol. 2019; 14(2):277-293. PMC: 6998394. DOI: 10.1002/1878-0261.12608. View

Seijo L, Peled N, Ajona D, Boeri M, Field J, Sozzi G . Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges. J Thorac Oncol. 2018; 14(3):343-357. PMC: 6494979. DOI: 10.1016/j.jtho.2018.11.023. View

Grunnet M, Sorensen J . Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 2011; 76(2):138-43. DOI: 10.1016/j.lungcan.2011.11.012. View

Aberle D, Adams A, Berg C, Black W, Clapp J, Fagerstrom R . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5):395-409. PMC: 4356534. DOI: 10.1056/NEJMoa1102873. View

10.

Patel V, Naik S, Naidich D, Travis W, Weingarten J, Lazzaro R . A practical algorithmic approach to the diagnosis and management of solitary pulmonary nodules: part 1: radiologic characteristics and imaging modalities. Chest. 2013; 143(3):825-839. DOI: 10.1378/chest.12-0960. View

11.

Vansteenkiste J, De Ruysscher D, Eberhardt W, Lim E, Senan S, Felip E . Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24 Suppl 6:vi89-98. DOI: 10.1093/annonc/mdt241. View

12.

Zhang Q, Luo J, Wu S, Si H, Gao C, Xu W . Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. Cancer Discov. 2020; 10(12):1842-1853. PMC: 8358981. DOI: 10.1158/2159-8290.CD-20-0047. View

13.

Tang Z, Ling Z, Wang C, Wu Y, Kong J . Serum tumor-associated autoantibodies as diagnostic biomarkers for lung cancer: A systematic review and meta-analysis. PLoS One. 2017; 12(7):e0182117. PMC: 5547718. DOI: 10.1371/journal.pone.0182117. View

14.

Leal A, van Grieken N, Palsgrove D, Phallen J, Medina J, Hruban C . White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. Nat Commun. 2020; 11(1):525. PMC: 6985115. DOI: 10.1038/s41467-020-14310-3. View

15.

Benjamini Y, Speed T . Summarizing and correcting the GC content bias in high-throughput sequencing. Nucleic Acids Res. 2012; 40(10):e72. PMC: 3378858. DOI: 10.1093/nar/gks001. View

16.

. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511(7511):543-50. PMC: 4231481. DOI: 10.1038/nature13385. View

17.

Tammemagi M, Katki H, Hocking W, Church T, Caporaso N, Kvale P . Selection criteria for lung-cancer screening. N Engl J Med. 2013; 368(8):728-36. PMC: 3929969. DOI: 10.1056/NEJMoa1211776. View

18.

Ulz P, Perakis S, Zhou Q, Moser T, Belic J, Lazzeri I . Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection. Nat Commun. 2019; 10(1):4666. PMC: 6789008. DOI: 10.1038/s41467-019-12714-4. View

19.

Kang H, Cho J, Lee S, Lee Y, Park J, Cho Y . Role of Low-Dose Computerized Tomography in Lung Cancer Screening among Never-Smokers. J Thorac Oncol. 2018; 14(3):436-444. DOI: 10.1016/j.jtho.2018.11.002. View

20.

Silvestri G, Vachani A, Whitney D, Elashoff M, Smith K, Ferguson J . A Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer. N Engl J Med. 2015; 373(3):243-51. PMC: 4838273. DOI: 10.1056/NEJMoa1504601. View